De Novo device
HemosIL Liquid Anti-Xa
Instrumentation Laboratory CO · Anti-Factor Xa Activity Test System, Apixaban (QLU, Class II) · First FDA decision Sep 17, 2020, newest Jun 23, 2023Anemia, clotting and blood disordersPulmonary embolism and deep vein thrombosisStroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
0
Naming "HemosIL Liquid Anti-Xa"
MAUDE reports
0
Brand "HemosIL Liquid Anti-Xa", since 2015
PubMed studies
9
Mentioning "HemosIL Liquid Anti-Xa"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing HemosIL Liquid Anti-Xa
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- HemosIL Liquid Anti-Xa510(k)
K223187 · Decided Jun 23, 2023 · 254 days after receipt
Device type: Anti-Factor Xa Activity Test System, Apixaban (QLU) · Laboratory Medicine & Pathology
- HemosIL Liquid Anti-XaNew device typeDe Novo
DEN190032 · Decided Sep 17, 2020 · 450 days after receipt
Device type: Anti-Factor Xa Activity Test System, Apixaban (QLU) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "HemosIL Liquid Anti-Xa", any status and sponsor, newest update first.
No registered device study names "HemosIL Liquid Anti-Xa".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "HemosIL Liquid Anti-Xa", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QLU
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "HemosIL Liquid Anti-Xa"[tiab]. The summary above synthesizes these.
- Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants.
Corrochano M, Acosta-Isaac R, Plaza M, et al. · PLoS One · 2022Observational Study, Research Support, Non-U.S. Gov't
- Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma.
Siriez R, Evrard J, Dogné JM, et al. · Int J Lab Hematol · 2019Clinical Trial
- Reagent-specific anti-Xa DOAC safety cutoffs can be established using multiple LMWH-calibrated anti-Xa assays.
Nieuwenstein T, Stoffer IP, Hellenbrand DLS, et al. · Clin Chem Lab Med · 2026
- The Impact of Dextran Sulfate on Anti-Xa Assay Outcomes after Unfractionated Heparin Reversal by Excessive Protamine.
Zhang J · Indian J Hematol Blood Transfus · 2025
- Rivaroxaban Levels in Patients' Plasmas are Comparable by Using Two Different Anti Xa Assay/Coagulometer Systems Calibrated with Two Different Calibrators.
Martinuzzo ME, Duboscq C, Lopez MS, et al. · Clin Lab · 2018
- DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M, Legnani C, Padrini R, et al. · Int J Lab Hematol · 2020Multicenter Study, Observational Study
- Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Dieplinger B, Egger M, Luft C, et al. · J Vasc Surg · 2018Comparative Study
- An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M, Legnani C, Testa S, et al. · Int J Lab Hematol · 2019
- Concentration Estimation of Apixaban and Rivaroxaban in Plasma From Patients Through Heparin-Calibrated Anti-Xa Assay Generated Different Results by Using 3 Reagent/Calibrators/Instrument Systems.
Martinuzzo ME, Berger CS, Sueldo E, et al. · Int J Lab Hematol · 2025
Other devices of this type
Also filed under product code QLU.
- INNOVANCE Anti-Xa (OPPU05)Siemens Healthcare Diagnostics Products GmbH · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.